We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
-0.68%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$237M
AUM Growth
+$7.37M
Cap. Flow
+$12.7M
Cap. Flow %
5.36%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
EIKN
Eikon Therapeutics
EIKN
+$26M
2
CYTK icon
Cytokinetics
CYTK
+$2.86M

Top Sells

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$16.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.39B
$135M 56.94%
4,778,581
– –
CYTK icon
2
Cytokinetics
CYTK
$11B
$33.2M 13.99%
503,295
+45,000
+10% +$2.86M
EIKN
3
Eikon Therapeutics
EIKN
$526M
$20.6M 8.67%
+1,943,682
New +$26M
LYEL icon
4
Lyell Immunopharma
LYEL
$317M
$16.1M 6.77%
800,399
– –
RLAY icon
5
Relay Therapeutics
RLAY
$4.31B
$9.95M 4.2%
1,000,000
– –
XENE icon
6
Xenon Pharmaceuticals
XENE
$6.43B
$9.3M 3.92%
160,000
– –
ALEC icon
7
Alector
ALEC
$167M
$8.36M 3.53%
3,887,200
– –
MAZE
8
Maze Therapeutics
MAZE
$1.61B
$4.68M 1.98%
156,901
-365,756
-70% -$16.1M

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
ICMM
Integrated Capital Management (Michigan) Bloomfield, Michigan $237M AUM 23.03% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
BCA
Bayshore Capital Advisors Tampa, Florida $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
TS
TradeWell Securities Fort Wayne, Indiana $237M AUM 24.02% 1-Year Est. Return
EA
Evolution Advisers Richmond, Virginia $237M AUM 12.93% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return

Foresite Capital Management IV's Q1 2026 Portfolio in Review

As of Q1 2026, Foresite Capital Management IV held 8 positions worth $237M, up 3.2% from $230M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management IV deployed $12.7M of net new capital in Q1 2026, opening 1 new position and adding to 1 existing holding. Its largest new stake was Eikon Therapeutics: 1,943,682 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Maze Therapeutics, an estimated $16.1M trimmed.

  • Foresite Capital Management IV's largest Q1 2026 buy was Eikon Therapeutics: 1,943,682 shares worth $20.6M.
  • Foresite Capital Management IV added most to Cytokinetics in Q1 2026, an estimated $2.86M increase.
  • Foresite Capital Management IV's biggest Q1 2026 reduction was Maze Therapeutics, cutting an estimated $16.1M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $237M portfolio in Q1 2026.
  • Foresite Capital Management IV opened 1 new position and closed 0 in Q1 2026.
  • Foresite Capital Management IV's portfolio value rose 3.2% quarter-over-quarter to $237M.

Based on Foresite Capital Management IV's 13F filing for Q1 2026, filed 15 May 2026.